No abstract available
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma / radiotherapy
-
Adenocarcinoma / surgery
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Chemotherapy, Adjuvant*
-
Combined Modality Therapy
-
Disease-Free Survival
-
Fatigue / chemically induced
-
Gonadotropin-Releasing Hormone / adverse effects
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Gonadotropin-Releasing Hormone / therapeutic use
-
Goserelin / adverse effects
-
Goserelin / therapeutic use*
-
Hot Flashes / chemically induced
-
Humans
-
Male
-
Multicenter Studies as Topic
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / mortality
-
Neoplasms, Hormone-Dependent / pathology
-
Neoplasms, Hormone-Dependent / radiotherapy
-
Neoplasms, Hormone-Dependent / surgery
-
Orchiectomy
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / mortality
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / radiotherapy
-
Prostatic Neoplasms / surgery
-
Quality of Life
-
Radiotherapy, Conformal
-
Randomized Controlled Trials as Topic
-
Sexual Dysfunction, Physiological / chemically induced
-
Survival Rate
-
Testosterone*
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Goserelin
-
Gonadotropin-Releasing Hormone
-
Testosterone